The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.

<h4>Introduction</h4>The efficacy of treatment with selective serotonin reuptake inhibitors in patients with major depressive disorder (MDD) can differ depending on the patient's serotonin transporter-linked polymorphic region (5-HTTLPR) genotype, and the effects of varying plasma c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tetsu Tomita, Norio Yasui-Furukori, Taku Nakagami, Shoko Tsuchimine, Masamichi Ishioka, Ayako Kaneda, Norio Sugawara, Sunao Kaneko
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0574598e14754dafbe870e7926792996
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0574598e14754dafbe870e7926792996
record_format	dspace
spelling	oai:doaj.org-article:0574598e14754dafbe870e79267929962021-11-18T08:18:13ZThe influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.1932-620310.1371/journal.pone.0098099https://doaj.org/article/0574598e14754dafbe870e79267929962014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24858363/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Introduction</h4>The efficacy of treatment with selective serotonin reuptake inhibitors in patients with major depressive disorder (MDD) can differ depending on the patient's serotonin transporter-linked polymorphic region (5-HTTLPR) genotype, and the effects of varying plasma concentrations of drugs can also vary. We investigated the association between the paroxetine plasma concentration and clinical response in patients with different 5-HTTLPR genotypes.<h4>Methods</h4>Fifty-one patients were enrolled in this study. The Montgomery-Asberg Depression Rating Scale (MADRS) was used to evaluate patients at 0, 1, 2, 4, and 6 weeks. The patients' paroxetine plasma concentrations at week 6 were measured using high-performance liquid chromatography. Additionally, their 5-HTTLPR polymorphisms (alleles S and L) were analyzed using a polymerase chain reaction with specific primers. We divided the participants into two groups based on their L haplotype: the SS group and the SL and LL group. We performed single and multiple regression analyses to investigate the associations between MADRS improvement and paroxetine plasma concentrations or other covariates for each group.<h4>Results</h4>There were no significant differences between the two groups with regard to demographic or clinical data. In the SS group, the paroxetine plasma concentration was significantly negatively correlated with improvement in MADRS at week 6. In the SL and LL group, the paroxetine plasma concentration was significantly positively correlated with improvement in MADRS at week 6 according to the results of the single regression analysis; however, it was not significantly correlated with improvement in MADRS at week 6 according to the results of the multiple regression analysis.<h4>Conclusion</h4>Among patients with MDD who do not respond to paroxetine, a lower plasma concentration or a lower oral dose of paroxetine might be more effective in those with the SS genotype, and a higher plasma concentration might be more effective in those with the SL or LL genotype.Tetsu TomitaNorio Yasui-FurukoriTaku NakagamiShoko TsuchimineMasamichi IshiokaAyako KanedaNorio SugawaraSunao KanekoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 5, p e98099 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tetsu Tomita Norio Yasui-Furukori Taku Nakagami Shoko Tsuchimine Masamichi Ishioka Ayako Kaneda Norio Sugawara Sunao Kaneko The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
description	<h4>Introduction</h4>The efficacy of treatment with selective serotonin reuptake inhibitors in patients with major depressive disorder (MDD) can differ depending on the patient's serotonin transporter-linked polymorphic region (5-HTTLPR) genotype, and the effects of varying plasma concentrations of drugs can also vary. We investigated the association between the paroxetine plasma concentration and clinical response in patients with different 5-HTTLPR genotypes.<h4>Methods</h4>Fifty-one patients were enrolled in this study. The Montgomery-Asberg Depression Rating Scale (MADRS) was used to evaluate patients at 0, 1, 2, 4, and 6 weeks. The patients' paroxetine plasma concentrations at week 6 were measured using high-performance liquid chromatography. Additionally, their 5-HTTLPR polymorphisms (alleles S and L) were analyzed using a polymerase chain reaction with specific primers. We divided the participants into two groups based on their L haplotype: the SS group and the SL and LL group. We performed single and multiple regression analyses to investigate the associations between MADRS improvement and paroxetine plasma concentrations or other covariates for each group.<h4>Results</h4>There were no significant differences between the two groups with regard to demographic or clinical data. In the SS group, the paroxetine plasma concentration was significantly negatively correlated with improvement in MADRS at week 6. In the SL and LL group, the paroxetine plasma concentration was significantly positively correlated with improvement in MADRS at week 6 according to the results of the single regression analysis; however, it was not significantly correlated with improvement in MADRS at week 6 according to the results of the multiple regression analysis.<h4>Conclusion</h4>Among patients with MDD who do not respond to paroxetine, a lower plasma concentration or a lower oral dose of paroxetine might be more effective in those with the SS genotype, and a higher plasma concentration might be more effective in those with the SL or LL genotype.
format	article
author	Tetsu Tomita Norio Yasui-Furukori Taku Nakagami Shoko Tsuchimine Masamichi Ishioka Ayako Kaneda Norio Sugawara Sunao Kaneko
author_facet	Tetsu Tomita Norio Yasui-Furukori Taku Nakagami Shoko Tsuchimine Masamichi Ishioka Ayako Kaneda Norio Sugawara Sunao Kaneko
author_sort	Tetsu Tomita
title	The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
title_short	The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
title_full	The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
title_fullStr	The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
title_full_unstemmed	The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
title_sort	influence of 5-httlpr genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/0574598e14754dafbe870e7926792996
work_keys_str_mv	AT tetsutomita theinfluenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT norioyasuifurukori theinfluenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT takunakagami theinfluenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT shokotsuchimine theinfluenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT masamichiishioka theinfluenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT ayakokaneda theinfluenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT noriosugawara theinfluenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT sunaokaneko theinfluenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT tetsutomita influenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT norioyasuifurukori influenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT takunakagami influenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT shokotsuchimine influenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT masamichiishioka influenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT ayakokaneda influenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT noriosugawara influenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder AT sunaokaneko influenceof5httlprgenotypeontheassociationbetweentheplasmaconcentrationandtherapeuticeffectofparoxetineinpatientswithmajordepressivedisorder
_version_	1718421904216293376

The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.

Ejemplares similares